Study: Lost weight rebounds quickly after stopping weight-loss jabs
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience.
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Generate Key Takeaways
Doctors around the world have been hailing "miracle" medications that make weight loss far easier, but new research suggests that after a person stops taking certain drugs, the weight tends to increase again rather quickly.
People who received the medication lost significant weight during the therapy, and this even continued to a small extent for a few weeks after stopping the medication, according to a research team led by Han Wu and Wenjia Yang from Peking University People's Hospital.
However, from the eighth week after the end of therapy, researchers said there was a marked weight gain that persisted for many weeks.
The extent of weight gain varies depending on the medication and lifestyle changes, according to the study, but there is a clear trend towards weight gain after stopping the medication.
This confirms existing findings, according to Stephan Martin, chief physician for diabetology and director of the West German Diabetes and Health Centre at the Association of Catholic Clinics in Düsseldorf, Germany.
He said that some manufacturers of the medications had also demonstrated this themselves through randomized studies. Test subjects were given the active substances for 10 weeks, after which some were switched to a placebo. This group "then continuously regained weight," Martin reported.
In the current study, the researchers from Beijing also referred to an investigation in which people who had completed a 36-week treatment with the active substance tirzepatide (GLP-1-RA) regained about half of the weight they had previously lost within a year of switching to a placebo.
The newly published meta-analysis summarised the results of 11 independent studies from around the world, including those on the drug orlistat, the combinations naltrexone/bupropion and phentermine/topiramate, as well as the group of GLP-1 receptor agonists. The data came from a total of 1,574 people in treatment groups and 893 in control groups.
GLP-1 receptor agonists (GLP-1-RA) are included in popular medications such as Wegovy and Ozempic. In some countries, they are approved for type 2 diabetes and some cases of obesity, and they are known as lifestyle drugs for achieving a slim figure.
These active substances, which are injected regularly, primarily prolong the time food stays in the digestive tract, thereby increasing the feeling of satiety. Side effects include gastrointestinal complaints.
One aspect of the study stands out: Those who initially experienced significant weight loss during therapy tended to regain more weight afterwards, even if they participated in programmes to change their lifestyle, such as eating and exercise habits.
"This does not surprise me," says Anja Hilbert, professor of behavioural medicine at Germany's Leipzig University Hospital. Similar experiences are seen, for example, in people who follow a very low-calorie diet — they also tend to regain more weight after the diet ends than those who undergo moderate calorie limits.
However, the expert noted that there were only a few participants for this aspect of the study. "The results of the study actually suggest that long-term, perhaps even lifelong use of the medication may be necessary to stabilise weight," Hilbert says.
"It is a long-term therapy," diabetologist Martin emphasizes. Anyone who believes they can lose weight with this therapy and then everything will be fine is mistaken. "You need this therapy permanently."
Some in the US health care system have raised concerns that many people may not be aware of this or may accept it.
According to studies, two-thirds of people treated for obesity, most of whom pay for the treatment themselves, stopped using the medication within a year.
"We don't know why: Maybe it becomes too expensive, maybe they have lost enough weight and believe it will now stay off," says Martin, who advocates for more overweight prevention rather than treating the consequences.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Aetna Marks 3 Years of Type 2 Diabetes Reversal through Virta Health, Thousands See Results
New data shows continued clinically significant outcomes, including improvements across blood sugar, medication reduction and weight loss PHOENIX, July 31, 2025--(BUSINESS WIRE)--Banner|Aetna, a joint venture health plan owned by Banner Health and Aetna, a CVS Health company, celebrates three years of investing in members by offering an evidence-based diabetes reversal initiative. In 2022, the insurer was an early adopter of Virta Health for diabetes reversal – the process of reducing blood glucose levels to below the threshold used to diagnose diabetes.1 Since then, the program enrollment has grown 290% and thousands of members have achieved sustainable health transformations while reducing their need for expensive weight loss medications, like Wegovy and Ozempic.2 The flexible app-based program uses a virtual model to address the root cause of metabolic disease through individualized nutrition plans that fit members' unique lifestyles, cultural background, dietary preferences, and budget. Thanks to the personalized approach and one-on-one expert support, participants are experiencing significant and lasting outcomes. Recent data shows that Banner|Aetna members saw meaningful metabolic health improvements after 365 days of program enrollment, including the following. Blood sugar reduction: On average, members saw a 0.97% reduction in A1C blood sugar levels.3 Every one-point decrease in A1C reduces the risk of long-term diabetes complications by up to 40%. Prescription reduction: Members eliminated 57% of diabetes medications (excluding metformin), including a 66% reduction in insulin dosages. Of those on insulin, 44% eliminated it completely.4 Clinically significant weight loss: 61% of members experienced clinically significant weight loss (5% or more); on average, members lost 8% of their body weight.5 Clinically significant weight loss can lead to better sleep, reduced inflammation, improved blood pressure, reduced risk of heart disease and positive impacts on arthritis and fatty liver disease. In addition to the diabetes reversal program demonstrating outstanding clinical results, Banner|Aetna's omnichannel outreach approach achieves 3x higher member engagement compared to industry averages.6 Through deep integration with Banner Health—one of Banner|Aetna's parent companies and Arizona's largest healthcare delivery system—the insurer leverages the Banner Health clinical and care management teams to refer eligible members into a diabetes management program. "The U.S. is facing a metabolic disease crisis. One in 10 people lives with diabetes, and most have type 2. One in three has prediabetes," explains Ed Clarke, MD, Banner|Aetna Medical Director and VP, CMO Banner Plans & Networks. "These conditions take a toll on the physical, emotional and financial health of millions of people in Arizona. That's why Banner|Aetna collaborated with Virta to offer members a holistic, non-pharmacological approach that puts disease reversal within reach. The feedback from members who have completed the program shows its dramatic impact on their lives. Not only do they gain a better understanding of disease management, but more importantly how they can take control health of their health." The results speak for themselves as members are achieving notable clinical outcomes helping them reclaim their lives, while also having a positive effect that ripples out to their families and the broader community. For Banner|Aetna member Shelby*, learning to use food as medicine has led to "amazing" changes in her life, including increased energy, better sleep, and weight loss. "I have learned how my body reacts to a wide array of foods and what I can eat to help it flourish," she explains. "I am very thankful for the support my coach provides every step of the way, and her encouragement that I am worth the hard work." Banner|Aetna currently offers type 2 diabetes reversal to eligible members of fully insured and Administrative Services Only groups. Additionally, Banner|Aetna self-funded employer groups can access Virta's prediabetes and obesity reversal offerings, which use the same innovative care model. About Banner|Aetna Banner|Aetna is a health insurance company focusing on bettering member outcomes at a lower cost, all while improving the overall member experience for employers and consumers in Arizona. The collaboration combines Banner Health's quality, local providers and delivery systems with Aetna's health-plan experience, care management and health information technology. Banner|Aetna is the brand name used for products and services provided by Banner Health and Aetna Health Insurance Company and Banner Health and Aetna Health Plan Inc. For more information about Banner|Aetna, visit About Banner Health Banner Health is one of the largest, secular nonprofit health care systems in the country. In addition to 33 hospitals, Banner also operates an academic medicine division, Banner – University Medicine, and Banner MD Anderson Cancer Center, a partnership with one of the world's leading cancer programs, MD Anderson Cancer Center. Banner's array of services includes a health insurance division, employed physician groups, outpatient surgery centers, urgent care locations, home care and hospice services, retail pharmacies, stand-alone imaging centers, physical therapy and rehabilitation, behavioral health services, a research division and a nursing registry. To make health care easier, 100% of Banner-employed doctors are available for virtual visits and patients may also reserve spots at Banner Urgent Care locations and can book appointments online with many Banner-employed doctors. Headquartered in Arizona, Banner Health also has locations in California, Colorado, Nebraska, Nevada and Wyoming. For more information, visit About CVS Health CVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of March 31, 2025, the Company had more than 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics, a leading pharmacy benefits manager with approximately 88 million plan members, and a dedicated senior pharmacy care business serving more than 800,000 patients per year. The Company also serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs. _____________________ 1 Riddle MC, Cefalu WT, Evans PH et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care 1 October 2021; 44 (10): 2438–2444. 2 Virta Health & Banner|Aetna Clinical Outcomes. March 31, 2025.3 Virta Health & Banner|Aetna Clinical Outcomes. February 27, 2025.4 Ibid.5 Ibid.6 Engagement data reported by Virta Health. January 2023-May 2025. * The member's uncompensated testimonial reflects the enrollee's experience with Virta Health. View source version on Contacts Media Contact: Sarah McLeodActivate Healthsmcleod@ Virta Healthpress@
Gizmodo
21 minutes ago
- Gizmodo
Potatoes Evolved From Tomatoes, Study Reveals
That's it. That's the news. Genome biologist Sanwen Huang knows a thing or two about potatoes. But his latest potato breakthrough may be his most shocking yet: potatoes are descended from tomatoes. In a Cell paper published today, Huang's team reports that the modern potato likely emerged about 9 million years ago, when tomato plants married the etuberosum, a potato-like species common to Chile. The origin of the modern potato has puzzled scientists for years, but the new results finally give plant genomists closure—while overturning a long-held belief that potatoes were solely descended from etuberosum. 'Yes, we revealed that the tomato is the mother of the potato,' Huang, a professor of agricultural genomics at the Chinese Academy of Agricultural Sciences, confirmed to Gizmodo. Etuberosum, a type of wild potato, looks a lot like the potato you might find on a grocery shelf. But it lacks a key element of potato anatomy: the tuber—an extended structure of the stem or root that enables potatoes and their relatives to store nutrients and reproduce. Confusingly, however, genomic analyses suggested potatoes had much in common with tomatoes, Huang explained. This hinted to scientists that the trio—potatoes, tomatoes, and etuberosum—were related, but the link wasn't exactly clear. Until, that is, Huang's team had a wild idea and decided to run with it. What if tomatoes and potatoes really were family and not just linked by some random quirk of nature? To test their hypothesis, Huang and colleagues analyzed 450 genomes from cultivated potatoes and 56 other species of wild potatoes, constructing over 3,000 family trees to illustrate the genetic relationship between the modern potato, tomatoes, and the etuberosum. They found that 50.66% of these family trees listed tomatoes as a sister to petota, the group of wild potatoes with tubers. Next, they ran an extensive statistical analysis to compare the tree against genetic data. The team realized that the most salient scenario is that the potato is a hybrid of tomatoes and etuberosum, with the tomato contributing significantly more to the potato's genetic makeup. Most surprising of all was that the potato's key tuber-forming genes emerged as a combination of genetic material it received from each parent—despite the fact that neither tomato nor etuberosum has tubers. Specifically, tomatoes gave potatoes the gene that tells the plant to make tubers, whereas etuberosum passed on a gene that helps control the growth of tubers. This unique genetic pathway could lead to future agricultural innovations for breeding potatoes that don't develop harmful mutations, Huang added. But that's still in the works, and the potato expert hopes to explore this genetic relationship in more detail. 'Next time you eat potatoes, thank a tomato—the ancient, perhaps, mother of the potato,' Huang said. 'DNA proves they're family!'
WIRED
22 minutes ago
- WIRED
Inside the Summit Where China Pitched Its AI Agenda to the World
Jul 31, 2025 11:04 AM Behind closed doors, Chinese researchers are laying the groundwork for a new global AI agenda—without input from the US. Three days after the Trump administration published its much-anticipated AI action plan, the Chinese government put out its own AI policy blueprint. Was the timing a coincidence? I doubt it. China's 'Global AI Governance Action Plan' was released on July 26, the first day of the World Artificial Intelligence Conference (WAIC), the largest annual AI event in China. Geoffrey Hinton and Eric Schmidt were among the many Western tech industry figures who attended the festivities in Shanghai. Our WIRED colleague Will Knight was also on the scene. The vibe at WAIC was the polar opposite of Trump's America-first, regulation-light vision for AI, Will tells me. In his opening speech, Chinese Premier Li Qiang made a sobering case for the importance of global cooperation on AI. He was followed by a series of prominent Chinese AI researchers, who gave technical talks highlighting urgent questions the Trump administration appears to be largely brushing off. Zhou Bowen, leader of the Shanghai AI Lab, one of China's top AI research institutions, touted his team's work on AI safety at WAIC. He also suggested the government could play a role in monitoring commercial AI models for vulnerabilities. In an interview with WIRED, Yi Zeng, a professor at the Chinese Academy of Sciences and one of the country's leading voices on AI, said that he hopes AI safety organizations from around the world find ways to collaborate. 'It would be best if the UK, US, China, Singapore, and other institutes come together,' he said. The conference also included closed-door meetings about AI safety policy issues. Speaking after he attended one such confab, Paul Triolo, a partner at the advisory firm DGA-Albright Stonebridge Group, told WIRED that the discussions had been productive, despite the noticeable absence of American leadership. With the US out of the picture, 'a coalition of major AI safety players, co-led by China, Singapore, the UK, and the EU, will now drive efforts to construct guardrails around frontier AI model development,' Triolo told WIRED. He added that it wasn't just the US government that was missing: Of all the major US AI labs, only Elon Musk's xAI sent employees to attend the WAIC forum. Many Western visitors were surprised to learn how much of the conversation about AI in China revolves around safety regulations. 'You could literally attend AI safety events nonstop in the last seven days. And that was not the case with some of the other global AI summits,' Brian Tse, founder of the Beijing-based AI safety research institute Concordia AI, told me. Earlier this week, Concordia AI hosted a day-long safety forum in Shanghai with famous AI researchers like Stuart Russel and Yoshua Bengio. Switching Positions Comparing China's AI blueprint with Trump's action plan, it appears the two countries have switched positions. When Chinese companies first began developing advanced AI models, many observers thought they would be held back by censorship requirements imposed by the government. Now, US leaders say they want to ensure homegrown AI models 'pursue objective truth,' an endeavor that, as my colleague Steven Levy wrote in last week's Backchannel newsletter, is 'a blatant exercise in top-down ideological bias.' China's AI action plan, meanwhile, reads like a globalist manifesto: It recommends that the United Nations help lead international AI efforts and suggests governments have an important role to play in regulating the technology. Although their governments are very different, when it comes to AI safety, people in China and the US are worried about many of the same things: model hallucinations, discrimination, existential risks, cybersecurity vulnerabilities, etc. Because the US and China are developing frontier AI models 'trained on the same architecture and using the same methods of scaling laws, the types of societal impact and the risks they pose are very, very similar,' says Tse. That also means academic research on AI safety is converging in the two countries, including in areas like scalable oversight (how humans can monitor AI models with other AI models) and the development of interoperable safety testing standards. But Chinese and American leaders have demonstrated they have very different attitudes toward these issues. On one hand, the Trump administration recently tried and failed to put a 10-year moratorium on passing new state-level AI regulations. On the other hand, Chinese officials, including even Xi Jinping himself, are increasingly speaking out about the importance of putting guardrails on AI. Beijing has also been busy drafting domestic standards and rules for the technology, some of which are already in effect. As Trump goes rogue with unorthodox and inconsistent policies, the Chinese government increasingly looks like the adult in the room. With its new AI action plan, Beijing is trying to seize the moment and send the world a message: If you want leadership on this world-changing innovation, look here. Charm Offensive I don't know how effective China's charm offensive will be in the end, but the global retreat of the US does feel like a once-in-a-century opportunity for Beijing to spread its influence, especially at a moment when every country is looking for role models to help them make sense of AI risks and the best ways to manage them. But there's one thing I'm not sure about: How eager will China's domestic AI industry be to embrace this heightened focus on safety? While the Chinese government and academic circles have significantly ramped up their AI safety efforts, industry has so far seemed less enthusiastic—just like in the West. Chinese AI labs disclose less information about their AI safety efforts than their Western counterparts do, according to a recent report published by Concordia AI. Of the 13 frontier AI developers in China the report analyzed, only three produced details about safety assessments in their research publications. Will told me that several tech entrepreneurs he spoke to at WAIC said they were worried about AI risks such as hallucination, model bias, and criminal misuse. But when it came to AGI, many seemed optimistic that the technology will have positive impacts on their life, and they were less concerned about things like job loss or existential risks. Privately, Will says, some entrepreneurs admitted that addressing existential risks isn't as important to them as figuring out how to scale, make money, and beat the competition. But the clear signal from the Chinese government is that companies should be encouraged to tackle AI safety risks, and I wouldn't be surprised if many startups in the country change their tune. Triolo, of DGA-Albright Stonebridge Group, said he expected Chinese frontier research labs to begin publishing more cutting-edge safety work. Some WAIC attendees see China's focus on open source AI as a key part of the picture. 'As Chinese AI companies increasingly open-source powerful AIs, their American counterparts are pressured to do the same,' Bo Peng, a researcher who created the open source large language model RWKV, told WIRED. Peng envisions a future where different nations—including ones that do not always agree—work together on AI. 'A competitive landscape of multiple powerful open-source AIs is in the best interest of AI safety and humanity's future,' he explained. 'Because different AIs naturally embody different values and will keep each other in check.' This is an edition of Zeyi Yang and Louise Matsakis' Made in China newsletter . Read previous newsletters here.
